SHOULDER INNOVATIONS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $SI in the last 7 days.
Gilde Healthcare Holding B.V. sold 25,097 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $22.61 ($22.60–$22.62, $0.57M total) across 3 trades over 2026-08-20 to 2026-08-24.
Shoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.
According to a Form 10-K filed May 13, 2026, Gilde Healthcare and related Dutch entities hold 2,212,207 shares of Shoulder Innovations, Inc. common stock, or 10.7% based on 20,738,226 shares outstanding as of May 6, 2026. The filing also reports open-market sales in late July to early August 2026, including 99,812 shares sold Aug. 4 at a weighted average $22.77.
Recent SI coverage spans insider activity, earnings and financial news.
In the last 30 days, SI insiders filed 12 SEC Form 4 transactions — no purchases and 12 sales ($4.9M). The most active reporter was Gilde Healthcare Holding B.V. with 9 filings. 25% of those filings were made under pre-arranged Rule 10b5-1 plans.
Gilde Healthcare Holding B.V. sold 25,097 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $22.61 ($22.60–$22.62, $0.57M total) across 3 trades over 2026-08-20 to 2026-08-24.
Q2 results and updated pipeline milestones reduce uncertainty on near-term profitability trajectory and extend the timeline for the robotic platform.
A major-holder stake update with disclosed open-market sales can shift perceived control and near-term supply overhang, but it is not an operating or fundamental change.
This is an insider (10% owner) indirect sale with no 10b5-1 plan disclosed, which can modestly affect near-term sentiment but is not a fundamental catalyst.
Guidance raise plus strong Q2 growth supports a near-term positive re-rating, but losses and rising opex keep volatility elevated.
alphai scores every news story that mentions SI with an AI model for sentiment and relevance, and aggregates insider trades from SHOULDER INNOVATIONS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Gilde Healthcare Holding B.V. sold 25,097 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $22.61 ($22.60–$22.62, $0.57M total) across 3 trades over 2026-08-20 to 2026-08-24.
1 min readShoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.
6 min readAccording to a Form 10-K filed May 13, 2026, Gilde Healthcare and related Dutch entities hold 2,212,207 shares of Shoulder Innovations, Inc. common stock, or 10.7% based on 20,738,226 shares outstanding as of May 6, 2026. The filing also reports open-market sales in late July to early August 2026, including 99,812 shares sold Aug. 4 at a weighted average $22.77.
2 min readGilde Healthcare Holding B.V. sold 9,433 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $22.63 ($22.60–$22.64, $0.21M total) across 2 trades over 2026-08-05 to 2026-08-06.
2 min readShoulder Innovations (NYSE: SI) reported Q2 2026 net revenue of $17.2 million, up 56% year over year, with gross margin of 78.3%. Full-year 2026 net revenue guidance was raised to $67 million to $69 million. Cash and marketable securities totaled $99.0 million as of June 30, 2026.
4 min readSiemens said it signed an agreement to acquire privately held US EDA software firm Precision Innovations. Siemens said the deal will add AI-powered chip planning and early design exploration using the OpenROAD framework to help semiconductor teams optimize power, performance and area, reduce iterations, and speed SoC feasibility analysis and time to market.
2 min readSHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook Generates First Half 2026 Revenue Growth of 60% Grand Rapids, MI – August 6, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commerc
6 min readGilde Healthcare Holding B.V. sold 110,563 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $22.76 ($22.71–$22.77, $2.52M total) across 2 trades over 2026-08-03 to 2026-08-04.
1 min readGilde Healthcare Holding B.V. sold 48,279 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $23.10 ($22.73–$23.36, $1.12M total) across 2 trades over 2026-07-30 to 2026-07-31.
2 min readBiotech shares hit 52-week highs on July 28, 2026. Incyte (INCY) rose over 9% to $132.58 after Q2 revenue of $1.67B, up 38% year over year, and raised full-year net sales guidance to $5.13B-$5.26B. Pulse Biosciences (PLSE) gained over 8% to $36.29. Other climbers included Shoulder Innovations (SI), Bioventus (BVS), and LB Pharmaceuticals (LBRX).
4 min read
